statnews.com·Apr 21, 2026
Kelonia Therapeutics has transformed from struggling to a successful acquisition by Eli Lilly for $3 billion, highlighting the challenges and potential rewards in the biotech industry. Additionally, BioAge is making strides in targeting inflammation to treat chronic conditions.
The article highlights Kelonia Therapeutics' journey from struggling to a $3 billion acquisition by Eli Lilly, emphasizing the potential for significant turnarounds in biotech companies. This suggests a strategic opportunity for investors and stakeholders in healthtech to identify and support biotech startups with promising but underutilized assets or strategies, as successful turnarounds can lead to substantial gains.